Compare NEO & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEO | INMD |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 842.0M |
| IPO Year | 2008 | 2018 |
| Metric | NEO | INMD |
|---|---|---|
| Price | $9.18 | $14.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | $13.38 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 2.0M | 768.1K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.63 | $1.74 |
| Revenue Next Year | $9.73 | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $12.72 |
| 52 Week High | $13.74 | $16.74 |
| Indicator | NEO | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 49.29 |
| Support Level | $7.42 | $13.27 |
| Resistance Level | $10.82 | $14.70 |
| Average True Range (ATR) | 0.40 | 0.31 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 84.81 | 62.78 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.